We are collecting information about and comparing two treatments (standards of care) for patients with GPA who are remission (reduced symptoms or have had no change in symptoms). We will evaluate how patients with GPA do if they are given 5 mg or 0 mg per day of prednisone.
60 individuals with granulomatosis with polyangiitis (GPA, also known as Wegener's granulomatosis) will be enrolled into this trial through the TAPIR trial website.
After participants have completed an online consent form, patients will download the Physicians' Packet that they will give to their physician. Patients will request medical record information from their doctor and send it to the TAPIR researchers.
Each participant will be assigned to either take 5 mg or 0 mg per day of prednisone. The chance of being assigned to either dose is 50/50 (and is random, like flipping a coin).
The patient is eligible for the TAPIR trial if the treating physician:
Agrees that either randomized treatment assignment (5 mg or 0 mg per day of prednisone) is appropriate for this participant
Participants will receive messages via email, text and social networking tools from the TAPIR trial team and will be prompted to enter specific information online through a personalized trial website:
Participation in text messages and social media networking with the TAPIR trial is completely optional and not required for a patient to participate in the study.
All participants will be followed for 6 months, regardless of whether their prednisone dose increases above their randomized trial dose.
To be eligible to participate, patients must:
Patients are not eligible for this trial if:
Learn more about the TAPIR trial team >
What if I am taking more than 20 mg of prednisone per day? Find out what you can do to prepare for the TAPIR trial
*other conditions may apply. Learn more